Clinical Trials for Mesothelioma Patients: Pemetrexed Disodium and Cisplatin Disease and Patient Characteristics

Read the disease and patient characteristics for this clinical trial being conducted to study the effects of pemetrexed disodium and cisplatin for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only. At this time, the study is currently being conducted only in Zurich, Switzerland.

Disease Characteristics:

• Histologically or cytologically confirmed malignant pleural mesothelioma o T1-3, N0-2, M0 disease according to International Mesothelioma Interest Group staging system

• No obvious invasion of mediastinal structures by CT scan (e.g., heart, aorta, spine, esophagus)

• No obvious widespread chest wall invasion o Resectable chest wall lesions allowed

Patient Characteristics:

• WHO performance score 0-1

• Fit for neoadjuvant therapy, surgery, and postoperative radiotherapy

• Creatinine clearance > 60 mL/min

• Hemoglobin = 10.0 g/dL

• WBC = 3,500/mm³

• Absolute neutrophil count = 1,500/mm³

• Platelet count = 100,000/mm³

• Bilirubin = 1.5 times upper limit of normal (ULN)

• AST and ALT = 1.5 times ULN

• Alkaline phosphatase = 1.5 times ULN

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for up to 12 months after completion of study treatment

• FEV_1 = 40% of predicted based on spirometry and lung perfusion scan, if necessary

• No serious underlying medical condition that would preclude study requirements (e.g., active autoimmune disease or uncontrolled diabetes)

Courtesy of ClinicalTrials.gov.

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney